Outlook Therapeutics Future Growth

Future criteria checks 5/6

Outlook Therapeutics is forecast to grow earnings and revenue by 57.1% and 52.1% per annum respectively while EPS is expected to grow by 58.5% per annum.

Key information

57.1%

Earnings growth rate

58.5%

EPS growth rate

Biotechs earnings growth	27.6%
Revenue growth rate	52.1%
Future return on equity	n/a
Analyst coverage	Good
Last updated	02 Dec 2024

Recent future growth updates

Recent updates

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Nov 03

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Aug 30

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Aug 10

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Jul 06

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Jul 05

Outlook Therapeutics: A One-Buck Lottery Ticket

Jun 09

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?

Apr 01

Earnings and Revenue Growth Forecasts

NasdaqCM:OTLK - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2027	196	110	N/A	N/A	3
9/30/2026	58	-2	N/A	N/A	3
9/30/2025	8	-70	N/A	-69	6
9/30/2024	N/A	-96	N/A	-71	6
6/30/2024	N/A	-94	-65	-65	N/A
3/31/2024	N/A	-159	-58	-58	N/A
12/31/2023	N/A	-51	-47	-47	N/A
9/30/2023	N/A	-59	-43	-43	N/A
6/30/2023	N/A	-60	-40	-40	N/A
3/31/2023	N/A	-57	-48	-48	N/A
12/31/2022	N/A	-70	-55	-55	N/A
9/30/2022	N/A	-66	-57	-57	N/A
6/30/2022	N/A	-65	-55	-55	N/A
3/31/2022	N/A	-60	-55	-55	N/A
12/31/2021	N/A	-53	-52	-52	N/A
9/30/2021	N/A	-53	-54	-54	N/A
6/30/2021	N/A	-50	-57	-57	N/A
3/31/2021	N/A	-40	-43	-43	N/A
12/31/2020	N/A	-45	-38	-38	N/A
9/30/2020	N/A	-49	-32	-32	N/A
6/30/2020	6	-49	-26	-26	N/A
3/31/2020	6	-51	-30	-30	N/A
12/31/2019	7	-45	-29	-29	N/A
9/30/2019	8	-36	-33	-32	N/A
6/30/2019	3	-38	-36	-35	N/A
3/31/2019	3	-43	-35	-33	N/A
12/31/2018	3	-40	-36	-34	N/A
9/30/2018	3	-48	-36	-33	N/A
6/30/2018	5	-43	-26	-25	N/A
3/31/2018	5	-39	N/A	-22	N/A
12/31/2017	4	-39	N/A	-18	N/A
9/30/2017	4	-40	N/A	-16	N/A
6/30/2017	1	-43	N/A	-26	N/A
3/31/2017	2	-68	N/A	-36	N/A
12/31/2016	2	-64	N/A	-39	N/A
9/30/2016	3	-63	N/A	-45	N/A
6/30/2016	3	-71	N/A	-46	N/A
3/31/2016	4	-53	N/A	-40	N/A
12/31/2015	3	-64	N/A	-36	N/A
9/30/2015	5	-53	N/A	-27	N/A
9/30/2014	9	-21	N/A	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OTLK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: OTLK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OTLK is expected to become profitable in the next 3 years.

Revenue vs Market: OTLK's revenue (52.1% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: OTLK's revenue (52.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OTLK's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 08:35
End of Day Share Price	2024/12/24 00:00
Earnings	2024/06/30
Annual Earnings	2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Outlook Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Edward Woo	Ascendiant Capital Markets LLC
Brian Kemp Dolliver	Brookline Capital Markets
Kumaraguru Raja	Brookline Capital Markets

Outlook Therapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target decreased by 9.5% to US$33.60

Forecast to breakeven in 2027

Price target decreased by 13% to US$38.50

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Forecast breakeven date pushed back to 2026

Recent updates

Outlook Therapeutics, Inc. Streamlines Operations

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc Announces Resignation of Russell Trenary as President

New major risk - Share price stability

Price target decreased by 9.5% to US$33.60

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Forecast to breakeven in 2027

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

New major risk - Financial position

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Insufficient new directors

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Price target decreased by 13% to US$38.50

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

New major risk - Share price stability

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Consensus revenue estimates decrease by 92%, EPS upgraded

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates decrease by 33%

Price target decreased by 61% to US$2.63

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Consensus EPS estimates fall by 12%

New major risk - Negative shareholders equity

Consensus EPS estimates upgraded to US$0.21 loss

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Price target decreased by 7.3% to US$6.13

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Price target decreased by 9.5% to US$6.33

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Consensus forecasts updated

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought US$111k worth of stock

Price target increased to US$7.25

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Price target decreased to US$6.33

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics: A One-Buck Lottery Ticket

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD